Over the past few days, as the rest of the stock market melted down, a revolution has been quietly brewing in the market for ...

Novo Holdings’ investment alongside Biocomposites’ existing shareholder, TA Associates, will help the company scale its ...

Novo Holdings has completed the previously announced acquisition of Catalent in a $16.5bn all-cash transaction. The European Commission (EC) gave its approval in early December 2024. Catalent's ...

Novo Holdings' $16.5 billion acquisition of US contract development and manufacturing organisation (CDMO) Catalent has been completed, after months of debate over potential antitrust issues.

As part of the transaction TA, Biocomposites' majority shareholder since 2017, will reinvest in the Company alongside new investor Novo Holdings and Biocomposites' management. The transaction ...

The Series C – which was led by Novo Nordisk's parent company Novo Holdings – follows a $15 million second round for the South San Francisco-based company in 2017 and a $15 million Series A in ...

A medical device company has secured investment from the owner of the developer of Ozempic and a private equity firm, to ...

Danish asset manager Novo Holdings, which is owned by Novo Nordisk Foundation (NNF), the majority voting shareholder of pharmaceuticals giant Novo Nordisk, is investing in Biocomposites alongside ...

HELLERUP, Denmark, LONDON and KEELE, England, March 3, 2025 /PRNewswire/ -- Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo ...

HELLERUP, Denmark, LONDON and KEELE, England, March 3, 2025 /PRNewswire/ -- Novo Holdings and TA Associates ("TA"), announced today that the parties have entered into an agreement for Novo Holdings to ...